Investors & Media

News

May 12, 2022

NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors

May 5, 2022

NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results

April 20, 2022

NGM Bio to Participate in Upcoming Investor Conferences

April 20, 2022

NGM Bio to Host the Second of Four Virtual R&D Events on April 27, 2022

April 8, 2022

NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio

March 31, 2022

NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors

March 21, 2022

NGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022

March 8, 2022

NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcoming 2022 AACR Annual Meeting

March 1, 2022

NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results

February 28, 2022

NGM Bio to Participate in the Cowen 42nd Annual Health Care Conference

Displaying 1 - 10 of 14

Contact Information

investor relations

ir@ngmbio.com

media relations

media@ngmbio.com